heart transplant | GenomeWeb

heart transplant

The firm missed analyst estimates for revenues and loss per share, citing a continued investment in its AlloSure NGS test for the wider-than-expected loss.

The company said sales of its AlloMap molecular diagnostic test were negatively affected during the quarter because of reduced collections from an external vendor.

The firm believes the diagnostics industry has not done a good job of communicating the value of medical tests to payors.

By scrutinizing more than 30,000 samples over dozens of studies, the team is exploring the genetics of transplantation complications.

The company reported total revenues of $7.1 million for Q2 and also missed the consensus Wall Street estimate on the bottom line. 

The molecular diagnostics firm beat the consensus Wall Street estimate on the top line but missed it on the bottom line. 

Diaxonhit, the exclusive European distributor of AlloMap, has selected a laboratory at Strasbourg University Hospitals to perform all testing on the continent. 

The test, which indicates risk of heart transplant rejection, is now available to patients in 11 additional states.

NEW YORK (GenomeWeb News) – XDx announced it has reached an agreement with Highmark Blue Cross Blue Shield to cover XDx's AlloMap test.

Researchers from the University of Western Ontario, in collaboration with Benitec Biopharma and stem cell firm Medistem, reported last month on the use of expressed RNAi technology to prolong the survival of an allogenic heart transplant by down-regulating certain genes involved

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.